Open lung biopsy for investigation of acute respiratory episodes in patients with HIV infection and AIDS

Robert F Miller, Wilfred B Pugsley, Meryl H Griffiths

Abstract

Background—Open lung biopsy (OLB) is rarely necessary for investigation of HIV positive patients with acute respiratory episodes because of the high yield from fiberoptic bronchoscopy with bronchoalveolar lavage (BAL).

Methods—A retrospective review of OLB in HIV positive patients admitted to a specialist inpatient unit with acute respiratory symptoms was carried out in order to define clinical indications, diagnostic yield, impact on management, complications and outcome.

Results—OLB was performed in 23 patients; 21 had undergone one or more bronchoscopies with BAL (5 also had negative results from transbronchial biopsy). Indications for OLB were: Group A, 15 patients thought clinically to have pneumocystis pneumonia but not responding to treatment; Group B, 4 patients with focal chest radiographic abnormalities; Group C, 4 patients with diffuse radiographic abnormalities and miscellaneous conditions. Preoperative PaO₂ (on air) ranged from 4.4 to 14.5 (mean = 9.5) kPa. The results of OLB were in Group A 5 patients had non specific interstitial pneumonitis (NIP), 1 also had Kaposi's sarcoma, 4 had pneumocystis pneumonia (1 also had bronchiolitis obliterans organising pneumonia [BOOP]), 3 had Kaposi's sarcoma and 1 had BOOP and emphysema, 1 had pulmonary infarction and no infection and 1 had normal lung tissue. In Group B diagnoses were NIP, B cell lymphoma, occult alveolar haemorrhage and *Pseudomonas aeruginosa* pneumonia with BOOP; In Group C 2 patients had NIP and 2 had pneumocystis pneumonia (1 also had cytomegalovirus pneumonitis). All patients survived surgery and none required mechanical ventilation. OLB results significantly affected management; in Group A inappropriate treatment was discontinued in 11 patients found not to have pneumocystis pneumonia, and alternative therapy was begun in the 4 with pneumocystis and in Groups B and C 6 patients began specific therapy; unnecessary therapy was avoided in one and antimicrobial treatment was modified in one.

Conclusions—Open lung biopsy in HIV positive patients with focal and diffuse radiographic abnormalities has a high

diagnostic yield and low morbidity. This investigation should be considered in those with acute respiratory episodes and negative results from bronchoscopic investigations or who have contra-indications to this procedure.

(Genitourin Med 1995;71:280-285)

Keywords: HIV; AIDS; lung biopsy

Introduction

Before the onset of the AIDS pandemic open lung biopsy was well established as a diagnostic tool for investigation of immunosuppressed patients with diffuse or focal pulmonary infiltrates.¹⁻³ Early in the AIDS pandemic open lung biopsy was also frequently performed in order to evaluate respiratory symptoms.⁴ Subsequently the perceived poor prognosis of patients undergoing biopsy, together with the realisation that diagnosis could frequently be made by fiberoptic bronchoscopy with bronchoalveolar lavage with or without transbronchial biopsy⁵⁻⁸ meant that open lung biopsy was rarely carried out.

Despite the high yield from bronchoalveolar lavage and transbronchial biopsy occasionally HIV positive patients with symptoms and signs of lower respiratory tract disease have negative results from these investigations and open lung biopsy is necessary to provide a diagnosis and enable specific treatment to be given. In this study we describe the clinical indications, diagnostic yield and impact on management, complications and outcome of open lung biopsy in HIV positive patients who had acute respiratory episodes, many of whom had negative bronchoscopic investigations.

Methods

Between October 1987 and March 1994 754 HIV-1 antibody positive patients were admitted to a specialist inpatient unit for investigation of acute respiratory episodes and were under the care of a respiratory physician. During this period 23 HIV antibody positive patients underwent open lung biopsy. In each case we recorded the clinical indications for biopsy, the type and number of any investigations performed and treatment given before biopsy, arterial blood gases (on air), the diagnosis obtained and impact on management, and complications arising from open lung biopsy.

Department of
Medicine
R F Miller

Department of
Histopathology,
University College
London Medical
School
M H Griffiths

Department of
Cardiothoracic
Surgery, Middlesex
Hospital, London
W1N 8AA, UK
W B Pugsley

Address correspondence to:
Dr R F Miller, Department
of Medicine, UCLMS, First
Floor Cross Piece,
Middlesex Hospital, London
W1N 8AA, UK.

Accepted for publication
9 June 1995

In those who underwent fiberoptic bronchoscopy before open lung biopsy the technique was performed as previously described,^{7,9} and bronchoalveolar lavage fluid routinely stained and cultured for bacteria, fungi, mycobacteria and viruses. Transbronchial biopsy specimens were taken without fluoroscopic control; four or more specimens being obtained on each occasion. Biopsies were stained and cultured as for bronchoalveolar lavage fluid.^{7,9}

Twenty two patients were male (21 were homosexual Caucasians and one was a heterosexual African) and the one female was a heterosexual Caucasian. Their ages ranged from 24 to 56 (mean 42.5) years. All had normal renal function, platelet count and clotting screen. Open lung biopsy was performed using the technique described by Venn *et al.*¹⁰ In summary surgery was performed via an anterolateral mini-thoracotomy, on the right if there was bilateral symmetrical disease radiographically, otherwise on the side of maximum radiographic abnormality. A representative portion of abnormal lung was taken. A chest drain was routinely left in place following closure, placed on 2kPa suction and removed at 24 to 48 hours. Each sample of lung tissue was split and part was processed for histology, the remainder was cultured to identify bacteria, fungi, mycobacteria and viruses.

Results

The clinical indications for open lung biopsy were; Group A, 15 patients who were thought clinically to have *Pneumocystis carinii* pneumonia. All had presented with typical symptoms

of non-productive cough, increasing exertional dyspnoea and fever.¹¹ Chest radiographs were abnormal showing diffuse infiltrates ranging in severity from subtle perihilar changes to more marked bilateral interstitial shadowing; patients were variably hypoxic. CD4 lymphocyte cell counts in these patients ranged from 10 to 260 (median 60)/mm.³ Despite specific anti-pneumocystis therapy, patients were deteriorating with worsening dyspnoea, falling arterial oxygen tensions (PaO₂), and many had increasing chest radiographic abnormalities (table); Group B, four patients who had fever and focal radiographic abnormalities. A diagnosis of non Hodgkin's lymphoma had been made, following lymph node and bone marrow biopsy, six months previously in patient 17. Patient 19 failed to respond to IV cefuroxime for an *Hemophilus influenzae* infection diagnosed at bronchoalveolar lavage; Group C, four patients with specific clinical problems. Patient 20 had extensive cutaneous Kaposi's sarcoma. He presented with dyspnoea and a chest radiograph showed diffuse bilateral interstitial infiltrates. He was thought clinically to have pulmonary Kaposi's sarcoma, for which chemotherapy was planned. Patient 21 had no AIDS defining illness, a CD4 count of 440 (normal 350–2200)/mm³ and a lymphocytic bronchoalveolar lavage sample, having presented with 12 weeks progressive dyspnoea and diffuse bilateral radiographic infiltrates. He was thought clinically not to have pneumocystis pneumonia, but sarcoidosis or a lymphoproliferative disorder were suggested by the bronchoalveolar lavage findings. Patient 22, a Caucasian female had presented with a severe pneumonia and was treated for presumed pneumocystis pneumonia with IV co-trimoxazole and methylprednisolone. Mechanical ventilation was required initially. Following an initial recovery, with improvement in PaO₂ and extubation, there was subsequent deterioration with worsening hypoxia and radiographic abnormalities. The final patient (23) presented with a pneumothorax, thus bronchoscopy was contra-indicated. The chest radiograph showed in addition, bilateral apical bullae and diffuse interstitial shadowing. Intercostal tube drainage of the pneumothorax was unsuccessful because of persistent air leak through the bullae. Surgical bullectomy and pleuradesis were carried out together with open lung biopsy.

Results of investigations performed with negative results and treatment received before open lung biopsy, arterial blood gases immediately before biopsy and the diagnosis provided by histological and microbiological analysis of lung tissue are shown in the table. It may be noted that no patient was mechanically ventilated at the time of biopsy and only patients 10, 12, 15 and 22 had received steroids.

Open lung biopsy provided diagnostic histological material in all patients. The results of open lung biopsy had a significant impact on management. In Group A in the 11 patients without *Pneumocystis carinii* pneumonia

Investigations, treatment and diagnosis in patients undergoing open lung biopsy

Group/No	Negative investigations prior to open lung biopsy	Treatment prior to open lung biopsy	PaO ₂ (kPa)	Final diagnosis
Group A				
1	BAL (× 2)	IV co-trimoxazole	8.7	Normal lung
2	BAL + TBB (× 2)	IV pentamidine	11.2	Kaposi's sarcoma
3	BAL (× 2)	Neb pentamidine	10.1	BOOP + emphysema
4	IS, BAL, BAL + TBB	IV co-trimoxazole	9.5	Granulomatous PCP
5	IS (× 2), BAL (× 3)	Neb pentamidine	13.9	Granulomatous PCP
6	IS, BAL	Neb pentamidine	8.0	PCP + BOOP
7	IS, BAL (× 3)	IV co-trimoxazole	9.9	NIP
8	IS, BAL (× 2)	Neb pentamidine	9.1	Granulomatous PCP
9	BAL	IV co-trimoxazole	8.7	Kaposi's sarcoma
10	BAL + TBB	IV co-trimoxazole	4.4	NIP
11	BAL	IV co-trimoxazole	11.4	NIP
12	BAL (× 2)	IV co-trimoxazole	6.0	NIP + Kaposi's sarcoma
13	BAL (× 2)	IV pentamidine	9.9	Pulmonary infarction
14	BAL	IV co-trimoxazole	9.9	Kaposi's sarcoma
15	BAL	IV co-trimoxazole	6.7	NIP
Group B				
16	BAL	-	10.7	Non-Hodgkin's lymphoma
17	BAL	-	10.3	Occult alveolar haemorrhage
18	BAL, BAL + TBB	-	14.5	NIP
19	BAL (× 2)	IV cefuroxime	11.6	<i>Pseudomonas aeruginosa</i> pneumonia + BOOP
Group C				
20	BAL + TBB	-	ND	NIP
21	BAL	-	9.1	NIP
22	NIL	IV co-trimoxazole	6.3	PCP + CMV pneumonitis
23	NIL	IV pentamidine	8.9	Granulomatous PCP

BAL = Bronchoalveolar lavage, TBB = Transbronchial biopsy, IS = Induced sputum, ND = not done, BOOP = Bronchiolitis obliterans organizing pneumonia, NIP = Non specific interstitial pneumonitis, PCP = *Pneumocystis carinii* pneumonia, CMV = cytomegalovirus, Neb = Nebulised, IV = Intravenous.

unnecessary and potentially toxic treatment was stopped and in addition the four patients with pulmonary Kaposi's sarcoma (including the one who also had non specific interstitial pneumonitis) began chemotherapy with vincristine and bleomycin, the patient with bronchiolitis obliterans organising pneumonia (BOOP) and paraseptal emphysema began prednisolone, as did the five patients with non specific interstitial pneumonitis. Three of the four patients with *P. carinii* pneumonia had been treated with nebulised pentamidine. This therapy was stopped and IV co-trimoxazole started in two patients (the third, who was allergic to co-trimoxazole, was given IV pentamidine). In the fourth patient, who was already receiving IV co-trimoxazole, therapy was continued unchanged. In Group B patient 16 with non Hodgkin's lymphoma began chemotherapy, patient 17 with occult alveolar haemorrhage avoided antibiotics,

patient 18 with non specific interstitial pneumonitis began prednisolone and the patient with *Pseudomonas aeruginosa* and BOOP discontinued cefuroxime and began ceftazidime. In Group C patient 20 avoided chemotherapy and instead received corticosteroids. This therapy was also given to patient 21. Patient 22 IV ganciclovir was added as treatment for cytomegalovirus pneumonitis and co-trimoxazole continued for the confirmed diagnosis of pneumocystis pneumonia. Patient 23 was given IV pentamidine (being allergic to co-trimoxazole).

All patients survived open lung biopsy and despite some patients being profoundly hypoxaemic none required post-operative mechanical ventilation. Lower respiratory tract infection requiring physiotherapy and antibiotics occurred post operatively in two patients, one of whom also had a persistent air leak and so the chest drain was left in place.

(a) Chest radiograph of Patient 4: Diagnosis = Granulomatous *Pneumocystis carinii* pneumonia. The arrow indicates the site of biopsy. (b) Chest radiograph of Patient 14: Diagnosis = Pulmonary Kaposi's sarcoma. The arrow indicates the site of biopsy. (c) Chest radiograph of Patient 15: Diagnosis = Non specific Interstitial Pneumonitis. The arrow indicates the site of biopsy. (d) Chest radiograph of Patient 21: Diagnosis = Non specific Interstitial Pneumonitis. The arrow indicates the site of biopsy.

on suction, for 72 hours. Two other patients had superficial wound infections not requiring wound toilet but responding to antibiotics. None of the patients with postoperative infections had received steroids. Subcutaneous emphysema or hydrothorax did not occur in any patient. All but two patients were eventually discharged from hospital; patients 12 and 13 died 42 and 69 days respectively after biopsy, from the effects of progressive HIV disease. Examples of chest radiographic abnormalities and the site of open lung biopsy are shown in the figure.

Discussion

We have previously undertaken a prospective study comparing the value of transbronchial biopsy and bronchoalveolar lavage in the diagnosis of pulmonary disease in HIV infected individuals with respiratory episodes.⁷ We found that bronchoalveolar alveolar lavage was superior to transbronchial biopsy for diagnosis of *P carinii* pneumonia (90 vs 56%) cytomegalovirus infection (100 vs 33%) and other pathogens. The diagnosis of pulmonary Kaposi's sarcoma was not made by either bronchoalveolar lavage or transbronchial biopsy. In no case was the diagnosis missed by lavage but made by transbronchial biopsy. We found a complication rate of 22% in those investigated with transbronchial biopsy, including pneumothorax and profuse haemorrhage (fatal in one patient); complications were especially likely in those with *P carinii* pneumonia. In contrast there were no significant complications in patients investigated with lavage alone.⁷ On the basis of this study and data from others,^{5,8} we perceived no cost/benefit advantage in continuing to carry out transbronchial biopsies in our patients and so stopped doing them at the end of 1989.

In this study we found that open lung biopsy produced a specific diagnosis in 22 patients, (a yield of 95%), with acute respiratory episodes and diffuse or focal radiographic abnormalities, most of whom had negative bronchoscopic investigations. These results are in keeping with other studies in patients immunosuppressed by HIV infection⁴ or by other causes,¹⁻³ with reported yield in those with diffuse radiographic infiltrates of between 83 and 95%, and up to 71% in those with focal infiltrates.^{1,4}

In a study from New York by Fitzgerald *et al*, 42 HIV positive patients underwent open lung biopsy, 29 had previously undergone fiberoptic bronchoscopy and bronchoalveolar lavage (18 had also undergone transbronchial biopsy) with negative results, four were thought clinically to be too ill for bronchoscopy or had abnormal coagulation results, and nine patients were deteriorating despite specific treatment for bronchoscopically diagnosed disease. Overall the diagnostic yield was 95%, in those with negative bronchoscopic investigations the commonest diagnoses were *Pneumocystis carinii* pneumonia in nine patients, Kaposi's sarcoma in seven,

interstitial fibrosis without infection in five and *Mycobacterium tuberculosis* in two patients; a specific diagnosis was obtained in all four who had not undergone bronchoscopy, including Kaposi's sarcoma in one case, but in those deteriorating despite a confirmed diagnosis, new diagnostic information requiring a change of treatment was obtained in only two patients.⁴

In our study the finding of Kaposi's sarcoma at open lung biopsy in four patients with diffuse radiographic infiltrates thought clinically to have *P carinii* pneumonia was not surprising as pulmonary Kaposi's sarcoma has been described mimicking this condition.^{12,13} Parenchymal lung involvement by Kaposi's sarcoma may also occur even if tracheobronchial disease is not evident at bronchoscopy.¹² The diagnosis of lung parenchymal Kaposi's sarcoma may be missed by transbronchial biopsy. This may be due to the patchy nature of parenchymal infiltration, together with the fact that lesions rarely show cytological features of malignancy and biopsy specimen crush artefact, haemorrhage and granulation tissue appearances may all mimic Kaposi's sarcoma.^{12,14} In one study, where transbronchial biopsy was routinely performed for diagnosis, the yield from this technique for pulmonary Kaposi's sarcoma was only 23%.¹⁴ The diagnosis of Kaposi's sarcoma was missed by transbronchial biopsy in the patient in our study, and in seven of the eight patients with this diagnosis in Fitzgerald's study.⁴ These data suggest that the need for open lung biopsy would not have been obviated in our patients with pulmonary Kaposi's sarcoma even if we had routinely performed transbronchial biopsy at bronchoscopy. Occult alveolar haemorrhage, found in one of our patients at open lung biopsy was once thought to be specific for the diagnosis of pulmonary Kaposi's sarcoma,¹³ but is now known to be a non specific finding in HIV positive patients with respiratory symptoms,¹⁵ and is also seen in *P carinii* pneumonia, bacterial and mycobacterial infection.

Four of our patients received nebulised pentamidine. This therapy was formerly very fashionable for the treatment of mild to moderate severity *P carinii* pneumonia.¹⁶ It is now known that patients receiving this form of therapy take longer to respond to treatment, compared with patients treated with IV co-trimoxazole; arterial blood gases and chest radiographs may worsen during the first 10-14 days of treatment, before eventual recovery.¹⁶ There is also a higher rate of early relapse following successful treatment and as treatment is not systemically delivered it may not suppress extra pulmonary pneumocystosis. For these reasons nebulised pentamidine is rarely, if ever, used now for treatment. If we had used IV co-trimoxazole or pentamidine instead of nebulised pentamidine in these patients then we might have anticipated recovery, without need for open lung biopsy, in the three who had *P carinii* pneumonia. The histological variant form granulomatous *P* pneumonia, diagnosed in four patients in

our study is well described in HIV positive patients. The diagnosis cannot be made by conventional histochemical staining of bronchoalveolar lavage fluid as the organisms do not lie within alveoli, instead they are "walled off" by palisades of histiocytes. The granulomatous response is patchy and transbronchial biopsy may also be negative.¹⁷ Molecular biological techniques used to identify *P. carinii* by DNA amplification using the polymerase chain reaction with *P. carinii*-specific oligonucleotide primers is still largely a research tool.¹⁸ Prospective comparisons have shown DNA amplification to be superior to conventional silver staining for detection of *P. carinii* in bronchoalveolar lavage fluid and induced sputum.^{19,20} More recently the technique has been successfully applied to patients with histologically variant granulomatous *P. carinii* pneumonia. Here, although silver staining of bronchoalveolar alveolar lavage fluid was negative and the diagnosis was made by open lung biopsy, retrospective analysis of lavage fluid by DNA amplification confirmed the diagnosis.²¹ With future refinements and appropriate calibration this technique may have a clinical role in diagnosis of *P. carinii* pneumonia, in particular patients with histologically atypical disease, and further reduce the need for open biopsy to confirm the diagnosis.

Non specific interstitial pneumonitis, which may clinically and radiographically simulate *P. carinii* pneumonia,²² has been identified in up to 38% of HIV positive patients undergoing bronchoscopy for evaluation of respiratory symptoms.²³ It is perhaps surprising that as the diagnosis can be made by transbronchial biopsy, results from this investigation were negative in the three patients in our study who underwent this procedure.

An alternative strategy in those patients with focal radiographic abnormalities might have been to use percutaneous lung biopsy under fluoroscopic or CT guidance. However, this procedure carries the risk of pneumothorax and uncontrolled bleeding and there are reports of cardiorespiratory arrest associated with the technique.²⁴ In contrast open lung biopsy affords the opportunity to view the lung directly and identify an abnormal area before obtaining tissue and larger samples may be obtained for analysis. Haemostasis can readily be achieved and the surgical pleural leak carefully closed: an intercostal drain placed on suction prevents pneumothorax.

The technique of open lung biopsy in our patients was safe. The complication rate was surprisingly low with minor wound infections in only two patients and chest infections in two others. These data are in contrast to other reports where wound infection and poor healing have been commoner.^{1,10,25} In these studies a higher proportion of patients had received glucocorticoids, a factor that might have encouraged infection or delayed healing. Of note none of our patients who had received steroids developed infections.

Cardiothoracic surgeons in other centres

may be asked by physician colleagues to perform open lung biopsy on HIV positive patients. They may question the usefulness of the procedure in terms of the risks and likely benefits to the patient. Our data, showing a high yield and low morbidity, support the use of this technique in selected patients. Based on these data our unit policy is now to proceed to open lung biopsy in patients with focal and diffuse radiographic abnormalities only if there are negative results from one or more fiberoptic bronchoscopy (with bronchoalveolar lavage) or if a patient has contraindications to bronchoscopy. In addition, in those with diffuse radiographic abnormalities, we would only consider open lung biopsy if there was clinical and/or radiographic deterioration despite specific anti-pneumocystis therapy.

In conclusion, open lung biopsy in HIV positive patients with symptoms and signs of lower respiratory tract disease and focal or diffuse radiographic abnormalities, with either negative results from bronchoscopic investigations or who have contra indications to the procedure, has a high diagnostic yield and results have a significant impact on management, enabling specific therapy to be given and unnecessary potentially toxic treatment to be avoided. The procedure is safe and has low morbidity.

We thank Jane Healing and Ursuline Loubser for typing the manuscript.

- 1 Jaffe JP, Maki DG. Lung biopsy in immunocompromised patients; one institution's experience and an approach to management of pulmonary disease in the compromised host. *Cancer* 1981;48:1144-53.
- 2 Michaelis LL, Leight GS, Powell RD, DeVita VT. Pneumocystis pneumonia: the importance of early lung biopsy. *Ann Surg* 1976;183:301-6.
- 3 Rosen PP, Martini N, Armstrong D. *Pneumocystis carinii* pneumonia. Diagnosis by lung biopsy. *Am J Med* 1975;58:794-801.
- 4 Fitzgerald W, Bevelacqua FA, Garay SM, Aranda CP. The role of open lung biopsy in patients with the acquired immunodeficiency syndrome. *Chest* 1987;91:659-61.
- 5 Broadus C, Dake MD, Stulbarg MS, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. *Ann Intern Med* 1985;102:747-52.
- 6 Blumenfeld W, Wager E, Hadley WK. Use of the transbronchial biopsy for diagnosis of opportunistic pulmonary infections in acquired immunodeficiency syndrome (AIDS). *Am J Clin Pathol* 1984;81:1-5.
- 7 Griffiths MH, Kocjan G, Miller RF, Godfrey-Faussett P. Diagnosis of pulmonary disease in human immunodeficiency virus infection: role of transbronchial biopsy and bronchoalveolar lavage. *Thorax* 1989;44:554-8.
- 8 Orenstein M, Webber CA, Cash M, Henrich AE. Value of bronchoalveolar lavage in the diagnosis of pulmonary infection in acquired immune deficiency syndrome. *Thorax* 1986;41:345-9.
- 9 Miller RF, Kocjan G, Buckland J, Holton J, Malin A, Semple SJG. Sputum induction for the diagnosis of pulmonary disease in HIV positive patients. *J Infection* 1991;23:5-15.
- 10 Venn GE, Kay PH, Midwood CJ, Goldstraw P. Open lung biopsy in patients with diffuse pulmonary shadowing. *Thorax* 1985;40:931-5.
- 11 Miller RF, Millar AB, Weller IVD, Semple SJG. Empirical treatment without bronchoscopy for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. *Thorax* 1989;44:559-64.
- 12 Miller RF, Tomlinson MC, Cottrill CP, Donald JJ, Spittle MF, Semple SJG. Bronchopulmonary Kaposi's sarcoma in patients with AIDS. *Thorax* 1992;47:721-5.
- 13 Fouret PJ, Touboul JL, Mayaud CM, Akoun GM, Roland J. Pulmonary Kaposi's sarcoma in patients with acquired immune deficiency syndrome: a clinicopathological study. *Thorax* 1987;42:262-8.
- 14 Meduri GU, Stover DE, Lee M, Myskowski PL, Carvelli JF, Zaman MB. Pulmonary Kaposi's sarcoma in the acquired immunodeficiency syndrome. *Am J Med* 1986;81:11-8.

- 15 Hughes-Davies L, Kocjan G, Spittle MF, Miller RF. Occult alveolar haemorrhage in Bronchopulmonary Kaposi's sarcoma. *J Clin Pathol* 1992;45:536-7.
- 16 Miller RF, Godfrey Fausset P, Semple SJG. Nebulised pentamidine as treatment for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. *Thorax* 1989;44:565-9.
- 17 Foley NM, Griffiths MH, Miller RF. Histologically atypical *Pneumocystis carinii* pneumonia. *Thorax* 1993;48:996-1001.
- 18 Wakefield AE, Pixley FJ, Banerji S, *et al.* Amplification of mitochondrial ribosomal RNA sequences from *Pneumocystis carinii* DNA of rat and human origin. *Mol Biochem Parasitol* 1990;43:69-76.
- 19 Wakefield AE, Pixley FJ, Banerji S, Miller RF, Moxon ER, Hopkin JM. Detection of *Pneumocystis carinii* with DNA amplification. *Lancet* 1990;336:451-3.
- 20 Wakefield AE, Guiver LA, Miller RF, Hopkin JM. DNA amplification on induced sputum samples for diagnosis of *Pneumocystis carinii* pneumonia. *Lancet* 1991;337:1378-9.
- 21 Wakefield AE, Miller RF, Guiver LA, Hopk JM. Granulomatous *Pneumocystis carinii* pneumonia: DNA amplification studies on bronchoscopic alveolar lavage samples. *J Clin Pathol* 1994;47:664-6.
- 22 Simmons JT, Suffredini AF, Lack EE, *et al.* Nonspecific interstitial pneumonitis in patients with AIDS: radiologic features. *AJR* 1987;149:265-8.
- 23 Suffredini AF, Ognibene FP, Lack EE, *et al.* Nonspecific interstitial pneumonitis: a common cause of pulmonary disease in the acquired immunodeficiency syndrome. *Ann Intern Med* 1987;107:7-13.
- 24 Craddock C, Pasvol G, Ball R, *et al.* Cardiorespiratory arrest and autonomic neuropathy in AIDS. *Lancet* 1987;ii:16-8.
- 25 Greenman RL, Goodall PT, King D. Lung biopsy in immunocompromised hosts. *Am J Med* 1975;59:488-96.